Therapeutic Response
ER positive and ERBB2 amplification status confers therapeutic sensitivity to Anastrozole in combination with Trastuzumab in patients with Invasive Breast Carcinoma.
Statements
| Source and description |
|---|
ER positive and ERBB2 amplification status confers therapeutic sensitivity to Anastrozole in combination with Trastuzumab in patients with Invasive Breast Carcinoma.
| Source and description |
|---|